Centessa Pharmaceuticals plc

LSE:0ACX Stock Report

Market Cap: US$2.3b

Centessa Pharmaceuticals Valuation

Is 0ACX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0ACX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0ACX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0ACX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0ACX?

Key metric: As 0ACX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0ACX. This is calculated by dividing 0ACX's market cap by their current book value.
What is 0ACX's PB Ratio?
PB Ratio4.6x
BookUS$499.14m
Market CapUS$2.28b

Price to Book Ratio vs Peers

How does 0ACX's PB Ratio compare to its peers?

The above table shows the PB ratio for 0ACX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.6x
GNS Genus
2x37.7%UK£1.1b
AVCT Avacta Group
3.6x-2.1%UK£175.6m
OXB Oxford Biomedica
6.8x93.2%UK£447.8m
SBTX SkinBioTherapeutics
9.9x40.8%UK£36.3m
0ACX Centessa Pharmaceuticals
4.6x-2.1%US$2.3b

Price-To-Book vs Peers: 0ACX is good value based on its Price-To-Book Ratio (4.6x) compared to the peer average (5.6x).

Price to Book Ratio vs Industry

How does 0ACX's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.46m
VAL ValiRx
0.6xn/aUS$2.78m
No more companies available in this PB range
0ACX 4.6xIndustry Avg. 2.8xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0ACX is expensive based on its Price-To-Book Ratio (4.6x) compared to the UK Biotechs industry average (2.8x).

Price to Book Ratio vs Fair Ratio

What is 0ACX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0ACX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0ACX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0ACX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$17.36
US$28.57
+64.6%
12.8%US$35.00US$24.00n/a7
Nov ’25US$15.06
US$26.14
+73.6%
20.6%US$35.00US$19.00n/a7
Oct ’25US$15.86
US$26.14
+64.9%
20.6%US$35.00US$19.00n/a7
Sep ’25US$13.45
US$14.50
+7.8%
19.0%US$20.00US$11.00n/a6
Aug ’25US$10.42
US$14.17
+35.9%
21.3%US$20.00US$11.00n/a6
Jul ’25US$9.33
US$14.20
+52.2%
23.3%US$20.00US$11.00n/a5
Jun ’25n/a
US$13.60
0%
29.6%US$20.00US$8.00n/a5
May ’25n/a
US$13.60
0%
29.6%US$20.00US$8.00n/a5
Apr ’25n/a
US$13.60
0%
29.6%US$20.00US$8.00n/a5
Mar ’25n/a
US$13.00
0%
31.9%US$20.00US$8.00n/a5
Feb ’25n/a
US$13.00
0%
31.9%US$20.00US$8.00n/a5
Jan ’25n/a
US$11.00
0%
20.7%US$15.00US$8.00n/a5
Dec ’24n/a
US$11.00
0%
20.7%US$15.00US$8.00n/a5
Nov ’24n/a
US$9.60
0%
37.6%US$15.00US$4.00US$15.065
Oct ’24n/a
US$8.80
0%
48.4%US$15.00US$4.00US$15.865
Sep ’24n/a
US$8.17
0%
50.7%US$15.00US$4.00US$13.456
Aug ’24n/a
US$7.08
0%
55.6%US$15.00US$4.00US$10.426
Jul ’24n/a
US$6.42
0%
41.8%US$11.00US$4.00US$9.336
Jun ’24n/a
US$5.90
0%
45.0%US$11.00US$4.00n/a5
May ’24n/a
US$5.80
0%
46.8%US$11.00US$4.00n/a5
Apr ’24n/a
US$5.80
0%
46.8%US$11.00US$4.00n/a5
Mar ’24n/a
US$5.75
0%
52.7%US$11.00US$4.00n/a4
Feb ’24n/a
US$5.75
0%
52.7%US$11.00US$4.00n/a4
Jan ’24n/a
US$6.00
0%
48.6%US$11.00US$4.00n/a4
Dec ’23n/a
US$6.00
0%
48.6%US$11.00US$4.00n/a4
Nov ’23n/a
US$6.00
0%
48.6%US$11.00US$4.00n/a4

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.20

7D

-16.8%

1Y

2.1%

Formycon

€844.9m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.35

7D

2.8%

1Y

-24.9%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$750.19

7D

0.5%

1Y

-5.7%